A LexisNexis analysis of over 26,000 patent families finds Chinese startups leading global innovation in humanoid robotics, with six of the top ten most active companies and rapid growth in patent filings
China has established a dominant position in humanoid robotics innovation, according to a recent LexisNexis patent analysis that evaluated more than 26,000 patent families worldwide. The report, which assessed patent portfolio size, technological relevance, and market coverage using the Patent Asset Index, found that Chinese companies now occupy six of the top ten spots for the most innovative startups in the sector. Shanghai-based Fourier and AgiBot lead the list, followed by LimX Dynamics and Pudu Robotics from Shenzhen, and Unitree Robotics from Hangzhou. Leju Robotics, also based in Shenzhen, ranks ninth. The remaining positions are held by three US companies-Figure AI, Apptronik, and Agility Robotics-and Germany's Agile Robots, the only European firm in the top ten.
Rather than focusing on public demonstrations or media attention, the LexisNexis study used patent data as a proxy for sustained technical innovation. The analysis highlights that by the end of 2025, Chinese entities accounted for 73% of the world's active morphology-related patent portfolio and 63% of global portfolio strength in this field. Over the past decade, China's patent activity in humanoid robotics has accelerated: filings in interaction systems doubled, those related to robot morphology increased by approximately 2.5 times, and patents in control and planning architectures grew fivefold. This surge reflects both increased research investment and a strategic focus on core robotic technologies.
While Chinese inventors are increasingly prominent in the field, the report notes that the United States continues to lead in average patent quality. US-based inventors are responsible for only 5% of active morphology-related patent families but contribute 11% of global portfolio strength, indicating a concentration of high-value patents. Many of the strongest portfolios belong to organizations whose main business extends beyond humanoid robotics, such as Fanuc, Alphabet, Nvidia, Kawasaki Heavy Industries, and Intuitive Surgical, as well as the Chinese Academy of Sciences. For nine of the ten leading organizations, humanoid robotics patents represent less than 10% of their total holdings. The exception is China's UBTECH, which has dedicated more than a quarter of its 370 relevant patent families to humanoid robotics, illustrating how focused patent investment can support commercial ambitions.
The competitive landscape is shaped not only by technical progress but also by regulatory and geopolitical factors. The South China Morning Post reports that the Trump administration recently imposed new restrictions on imports of robots and power inverters, citing national security and supply chain concerns. In parallel, the US House of Representatives has passed legislation barring the Pentagon from procuring or operating humanoid robotic systems linked to designated foreign adversaries, including China. These measures reflect growing unease about technological dependence and dual-use risks, even as Chinese companies expand their global patent footprint.
Patent data, while not a direct measure of deployed capability, offers insight into which organizations are investing in foundational technologies likely to shape future markets. The LexisNexis report argues that combining patent strength, technology classification, and business context can help identify the companies best positioned for commercial leadership. This approach complements other forms of technical evaluation, such as laboratory demonstrations and benchmark testing. For example, recent advances in full-body humanoid robot control, such as those described in Science Report's coverage of Gemini Robotics 2, illustrate how software and hardware innovation are converging across regions.
According to the LexisNexis analysis, China's rapid growth in patent filings is not matched by a corresponding lead in patent quality, which remains concentrated in the United States and a handful of multinational firms. The report also notes that many of the most valuable patents are held by companies whose primary business is not humanoid robotics, raising questions about the pace and direction of commercial deployment. As competition intensifies, the interplay between technical innovation, regulatory policy, and global supply chains will likely determine which organizations can translate patent portfolios into operational systems and market share.
Patent analysis is a common method for tracking innovation in fields where public demonstrations may not capture the full scope of technical progress. By examining the number, relevance, and market coverage of patent families, analysts can estimate which organizations are investing in foundational research and development. However, patents do not guarantee successful deployment or commercial viability. Many patented technologies remain untested outside the laboratory, and the value of a patent portfolio depends on factors such as enforceability, regulatory approval, and integration with existing systems. In robotics, where real-world performance and safety are critical, patent strength is only one indicator among many.
